Table 2.

Study outcomes by treatment arm

	Arm 1 (N=25) 12 weeks SOF+PR		Arm 2 (N=25) 24 weeks SOF+R		p-value
Primary outcome
Treatment completion, n(%)	22	88.0	22	88.0	>0.99
Secondary outcomes
Sustained virologic response*, n(%)	22	88.0	15	60.0	0.05
Median number of serious adverse events, IQR	0		0
Median change in insulin resistance (HOMA-IR), IQR	1.2	-0.1, 9.1	0.1	-1.3, 6.1	0.30
Exploratory outcomes
Percentage completed doses, n(%)
0–30%	3	12.0	3	12.0
75–90%	3	12.0	2	8.0
>90–95%	2	8.0	4	16.0	0.93
>95%-100%	17	68.0	16	64.0
Percentage observed doses received†, n(%)
70–90%	0	0	3	12.0
>90–95%	4	16.0	3	12.0	0.31
>95–100%	21	84.0	19	76.0
Median change in self-rated health state VAS †, IQR	0	-5, 10	5	-10, 8	0.58

^*Intent-to-treat approach (missing=no sustained virologic response)

^†Out of completed doses

VAS: visual analogue scale with range from 0 (worst health state) to 100 (best health state); ^†measured using the EQ 5D-3L instrument